Cynata Therapeutics Limited is an Australian stem cell and regenerative medicine company developing a therapeutic stem cell platform technology, Cymerus™, using discoveries made at the University of Wisconsin-Madison (UWM). Cynata is using its proprietary Cymerus technology to produce potent, consistent mesenchymal stem cells (MSCs) at scale to address critical shortcomings in existing methods of production of MSCs () for therapeutic use. Today, we sit down with Dr. Ross Macdonald (MD & CEO) & Dr. Kilian Kelly (COO) to understand Cynata’s exciting pipeline of clinical opportunities including the planned Phase 2 trial in Graft vs. Host Disease (GvHD) which just received Investigational New Drug (IND) approval in the US.
Key elements boosting Fiducian Group’s (ASX:FID) optimism
- October 04, 2022 11:41 AM AEDT
- Mohammad Zaid
ASX 200 opens higher; materials, energy, tech gain
- October 04, 2022 11:11 AM AEDT
LIMITED TIME OFFER!
SIGN UP NOW AND GET A
AU$25 DAVID JONES eGIFT CARD* FREE
*David Jones eGift Card Terms and Conditions Apply. Kalkine Media and its related affiliates/entities hereby disclaim any and all kinds of express/implied liabilities as regards your usage of the David Jones eGift Card.
GET YOUR eGIFT CARD
Dear , Thank You For Your Interest.
Our records show that you are already a subscribed user of either Kalkine Media or Kalkine Pty Ltd. Please note that this offer is valid for new users only.
Continue exploring Kalkine Media for latest news and insights.
You have Successfully Signed up on Kalkine Media.
You are Just a Step Away from your David Jones Free eGift Card.
Verify Now with the OTP sent on your email and mobile number.
Verify Your email and mobile number
Create Your Password
Your AU$25 David Jones FREE eGift Card is Ready.
The Card will be sent on your registered email id. Enjoy and Keep Exploring Kalkine Media for all the Upcoming Offers & Insights.